KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K.
Marin D, et al.
Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16.
Leukemia. 2012.
PMID: 21844874